Seymour Howard Fein - 10 Jul 2026 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Reporting relationship: CRO/CMO
Issuer ticker: OTLC
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 16:00:18 UTC
Source filing: View source filing
Reporting owner signature: /s/ Seymour Fein

Key filing fact

Seymour Howard Fein filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 23 Jul 2026.

Key facts

This page summarizes Seymour Howard Fein's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2026, 16:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002147180 Primary reporting owner

Fein Seymour Howard

Relationship: CRO/CMO
Address: 29397 AGOURA RD SUITE 107, AGOURA HILLS
Signature: /s/ Seymour Fein
Signature date: 23 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLC transaction Derivative

Restricted stock Units

Award

Transaction value
Shares: +250
Change %
Price: $0.000000^*
Shares after: 250
Date: 10 Jul 2026
Ownership: Direct
Underlying class: Series A Preferred Stock
Underlying amount: 250
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

Footnote F2

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.